Gilead Sciences, Inc. (NASDAQ: GILD) is contending with an ageing pipeline, but reports of testing for one of the company's antiviral drugs for the Wuhan coronavirus, aka 2019-nCoV, has provided a shot in the arm for the stock.
Testing Yet-To-Be Approved Treatment
Gilead said Friday it's working closely with global health authorities, including the FDA, CDC, China CDC and WHO, and with individual researchers and clinicians to contribute its antiviral expertise and resources to help patients and communities fight 2019-nCoV.
The company has provided remdesivir, an experimental antiviral therapy that has not yet been licensed or approved anywhere globally, for use in a small number of patients with 2019-nCoV for emergency treatment in the absence of any approved treatment options, the statement said.
Gilead clarified that this …
Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.